公开(公告)号：US20170029521A1

公开(公告)日：2017-02-02

申请号：US15197496

申请日：2016-06-29

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Tom VINK ,  Janine SCHUURMAN ,  Paul PARREN ,  Rob AALBERSE ,  Marijn VAN DER NEUT KOLFSCHOTEN

IPC: C07K16/28 ,  A61K51/10 ,  A61K47/48

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20210061919A1

公开(公告)日：2021-03-04

申请号：US16947021

申请日：2020-07-15

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Tom VINK ,  Janine SCHUURMAN ,  Paul PARREN ,  Rob AALBERSE ,  Marijn VAN DER NEUT KOLFSCHOTEN

IPC: C07K16/28 ,  A61K51/10 ,  C07K16/00 ,  A61K47/68 ,  C07K16/16 ,  C07K16/18

Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).